The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.
The company welcomes in 2021 with the failure of a pivotal study of its pipeline lead, telaglenastat.
Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.